title: How to help your patients lose weight: current therapy for obesity.
abstract: Obesity is epidemic and dangerous. Weight loss is difficult but worth the effort. Although new weight-loss drugs are available, there are no magic bullets: to lose weight and keep it off, people must eat less and exercise more. This article presents a practical approach on how physicians can help their patients lose weight through diet, behavior modification, and adjunctive pharmacologic therapy. An appropriate initial goal is to lose 5% to 10% of one's baseline weight over 3 to 6 months. Drug therapy should not be used in isolation, but it can be an adjunct to diet, exercise, and behavior modification if a patient is committed and able to make necessary changes in eating and activity, and if the patient has a BMI of 30 or higher or a BMI greater than 27 with weight-related comorbid conditions. Anorectic therapy is unlikely to succeed and should be stopped if the patient does not lose at least 4 lb in the first 4 weeks of therapy. Orlistat is unlikely to be of benefit if patients do not lose at least 3% of their baseline weight by 12 weeks. Because obesity is a chronic disease, drug treatment should be continued indefinitely. The physician and patient must understand the intention to treat long-term. The weight loss plan devised should improve upon previous plans: for example, implementing a regular, convenient exercise program that had not been included in the past, or offering pharmacotherapy.
authors.affiliation: University Hospitals Health System, Cleveland, USA. weissfamily@ameritech.net
authors.forename: D
authors.initials: D
authors.lastname: Weiss
mesh_terms: D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000627:therapeutic use*; D001067:Appetite Depressants / Q000627:therapeutic use*; D001521:Behavior Therapy; D002908:Chronic Disease; D003503:Cyclobutanes / Q000627:therapeutic use; D004038:Diet, Reducing; D015444:Exercise; D015390:Gastric Bypass; D006801:Humans; D007783:Lactones / Q000627:therapeutic use; D009765:Obesity / Q000175:diagnosis / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy*; D000077403:Orlistat; D015995:Prevalence; D016032:Randomized Controlled Trials as Topic; D014481:United States / Q000453:epidemiology
chemical_list: D019440:Anti-Obesity Agents; D000928:Antidepressive Agents; D001067:Appetite Depressants; D003503:Cyclobutanes; D007783:Lactones; D000077403:Orlistat; C058254:sibutramine